Can I Take Alpha-Lipoic Acid with Trazodone?

What trazodone is, and how people take it

Trazodone is an FDA-approved antidepressant in the serotonin antagonist and reuptake inhibitor (SARI) class, approved for major depressive disorder at doses generally in the 150-400 mg/day range. At much lower doses (commonly 25-150 mg at bedtime), it is prescribed off-label for insomnia, a widespread practice because it is not a controlled substance and does not carry the same dependence profile as benzodiazepine-receptor agonists.

Trazodone blocks serotonin 5-HT2A receptors and histamine H1 receptors, producing sedation, and it has weak alpha-1 adrenergic blocking activity. That alpha-1 blockade is the mechanistic reason trazodone can cause orthostatic hypotension, and it is also the reason it is discussed here: alpha-1 adrenergic signaling is part of how the body senses and corrects a falling blood glucose level.

What alpha-lipoic acid is, and why it overlaps with trazodone use

Alpha-lipoic acid (ALA), also called thioctic acid, is produced naturally in the body as a mitochondrial cofactor and is sold as an oral supplement, typically 200-600 mg/day, marketed for antioxidant support, metabolic health, and peripheral neuropathy symptoms. The FDA has not approved ALA for any indication in the United States; regulatory status for high-dose intravenous ALA differs in some other jurisdictions, and readers should check current European Medicines Agency material directly rather than relying on any single secondary summary (EMA).

People on trazodone for depression or insomnia frequently have overlapping metabolic conditions, insulin resistance, prediabetes, or diabetic neuropathy, which is why ALA use alongside trazodone comes up often enough to deserve a direct answer rather than a blanket "ask your doctor."

The core question: does ALA add to trazodone's effect on blood sugar?

This is the interaction with the clearest mechanistic basis, even though direct combination data (ALA plus trazodone specifically, in humans) does not appear to exist in the literature reviewed for this page.

What is established: ALA has insulin-sensitizing activity, generally attributed to activation of AMP-activated protein kinase (AMPK) and increased glucose uptake in skeletal muscle. This effect has been studied in people with type 2 diabetes, generally at doses in the 600 mg/day range, and modest reductions in fasting glucose have been reported in that population. Separately, trazodone's alpha-1 adrenergic blocking activity is a recognized part of its side-effect profile (contributing to orthostatic hypotension), and adrenergic signaling is part of the body's normal defense against hypoglycemia.

What is plausible but not established: that combining the two produces clinically meaningful additive hypoglycemia in practice. This is a reasonable pharmacological inference, not a demonstrated clinical finding. We did not find a controlled trial or case series studying trazodone plus ALA together, and the trazodone prescribing information should be checked directly for any listed glucose-related warnings before treating this as settled.

Who this matters most for:

• People with type 1 or type 2 diabetes, especially those on insulin or sulfonylureas
• People with prediabetes on metformin
• Adults over 65, whose glucose counter-regulation is already often blunted
• Anyone fasting, on a very low-carbohydrate diet, or otherwise prone to low blood sugar

For a healthy, non-diabetic adult taking trazodone 50-100 mg at bedtime for insomnia, the absolute added risk from starting ALA at a modest dose looks low based on what is known about each agent individually. A baseline fasting glucose is still a reasonable, low-cost precaution before adding ALA if there is any personal or family history of glucose dysregulation.

The thyroid hormone question

A separate line of research has examined ALA's effect on thyroid hormone levels. Some studies, largely older and with mixed methodology, report that ALA supplementation can lower circulating free T4 without a compensatory rise in TSH. The size of this effect varies substantially across the studies we could locate, and we are not confident enough in any single number to repeat one here as though it were settled; a clinician relying on this point should pull the primary literature rather than a secondary summary.

Why this matters in a trazodone context specifically: trazodone itself is not known to act on the hypothalamic-pituitary-thyroid axis. The concern is indirect. Patients being treated with trazodone for depression sometimes have coexisting subclinical hypothyroidism. If ALA lowers free T4 further, worsening mood or energy symptoms could be mistaken for trazodone not working, prompting an unnecessary dose increase rather than a thyroid recheck. Anyone on levothyroxine or with known thyroid disease who wants to add ALA should ask their prescriber about rechecking TSH and free T4 several weeks after starting, rather than assuming the current dose of thyroid medication will remain adequate.

Is there a pharmacokinetic interaction (does one change blood levels of the other)?

Trazodone is metabolized predominantly through CYP3A4, with a minor contribution from CYP2D6. For a pharmacokinetic interaction to occur, ALA would need to meaningfully inhibit or induce one of these enzymes at doses used in supplements. We did not find strong, specific evidence that oral ALA does this at typical supplement doses. Readers and clinicians who need a definitive answer on enzyme inhibition constants should consult a current drug-interaction database or the NIH's compound information resources directly rather than a general secondary claim (NCATS).

Trazodone is highly protein-bound in plasma (roughly 89-95%, per standard pharmacology references). Displacement from protein binding by ALA is theoretically possible with any competing compound, but we found no case reports or trial data documenting this specifically for trazodone and ALA, and no reason from the available evidence to treat it as a practical concern.

The practical takeaway: the clinically important overlap between trazodone and ALA is pharmacodynamic (both touch blood glucose regulation through separate mechanisms), not pharmacokinetic (ALA is unlikely to change how much trazodone is in the bloodstream).

Evidence boundary: what is known, plausible, and unestablished

• Established: ALA has insulin-sensitizing, glucose-lowering pharmacology, studied mainly in people with type 2 diabetes. Trazodone has alpha-1 adrenergic blocking activity associated with orthostatic hypotension.
• Plausible, not demonstrated in combination: additive hypoglycemia risk when ALA and trazodone are taken together, inferred from each agent's separate mechanism rather than from a direct trial or case series of the combination.
• Reported in some studies but inconsistent and not confirmed at typical supplement doses in the general population: ALA-associated reduction in free T4.
• Not established: any pharmacokinetic (blood-level) interaction between trazodone and ALA through CYP3A4, CYP2D6, or protein-binding displacement.
• Not addressed by any major U.S. or international guideline by name: we did not identify a diabetes, endocrinology, or psychiatric guideline that specifically addresses trazodone plus ALA co-administration. General diabetes standards of care call for monitoring when a patient's regimen changes, which would reasonably include adding a glucose-active supplement, but that is a general principle applied here, not a trazodone-ALA-specific recommendation.

Evidence-status interaction assessment

Practical guidance if you are considering both

Neither compound necessarily requires a dose change simply because the other is present. Reasonable, low-effort steps for someone who is otherwise healthy:

• Start ALA at a lower end of the typical range (roughly 200-300 mg/day) rather than jumping to 600 mg/day, since glucose effects appear to scale with dose.
• Take ALA on an empty stomach as usually directed (commonly 30 minutes before a meal), and take trazodone at its usual bedtime schedule. This naturally separates peak blood levels of the two by several hours for most people, which is a reasonable, low-cost precaution even though no trial has specifically tested a required separation window for this pair.
• If starting ALA while on trazodone, a baseline fasting glucose (and HbA1c if there is any personal risk factor) is a sensible precaution; repeating it after a few weeks catches an effect early if one appears.
• If there is any personal or family history of thyroid disease, or current use of levothyroxine, ask about a follow-up TSH and free T4 several weeks after starting ALA rather than waiting for symptoms.

When to involve a prescriber before starting ALA

Contact the clinician managing trazodone before adding ALA if any of the following apply:

• Diabetes, prediabetes, or use of any glucose-lowering medication (insulin, sulfonylurea, GLP-1 agonist, SGLT-2 inhibitor, metformin)
• Known thyroid disease or use of levothyroxine
• Trazodone dose above the low range typically used for insomnia
• Age 65 or older
• A history of hypoglycemic episodes on any prior regimen
• Any new dizziness, shakiness, sweating, or palpitations after starting ALA, which could indicate low blood sugar and warrants prompt evaluation rather than waiting for a scheduled follow-up

For an otherwise healthy adult on low-dose trazodone for sleep, with normal baseline glucose, starting ALA cautiously and monitoring is a reasonable approach, but telling the prescriber about the supplement is still standard practice regardless of perceived risk. General published guidance for dietary supplement users is a useful starting point for how to think about supplement safety more broadly.